ObsEva (OBSV) Stock Price, News & Analysis

Company Overview

ObsEva SA is a clinical-stage biopharmaceutical company headquartered in Geneva, Switzerland, that focuses on developing novel treatments for women’s reproductive health and pregnancy-related disorders. Founded in 2012, the company seeks to address significant unmet medical needs in areas such as endometriosis, preterm labor and embryo implantation support. ObsEva’s research platform is built around small‐molecule modulators of hormones and receptors involved in reproductive physiology.

The company’s most advanced programs include nolasiban (OBE001), an oral oxytocin receptor antagonist designed to improve implantation rates in in vitro fertilization (IVF) procedures; OBE2109, an orally available GnRH antagonist targeting pain and inflammation associated with endometriosis; and OBE022, a selective prostaglandin F2α receptor antagonist for the prevention of preterm labor. These candidates are being evaluated in Phase II and Phase III clinical trials, with the goal of delivering first-in‐class treatment options where current therapies are limited.

ObsEva maintains its Nasdaq listing under the ticker OBSV and operates in key markets across Europe and North America. The company collaborates with academic institutions and industry partners to advance its pipeline and employs a management team with extensive experience in reproductive biology, clinical development and commercial strategy. ObsEva’s mission is to bring new therapeutic solutions to women and families facing the challenges of reproductive health and pregnancy complications.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 200 shs
• Average Volume: 8.94 million shs
• Market Capitalization: $7.94 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

OBSV Stock Analysis - Frequently Asked Questions

How were ObsEva's earnings last quarter?

ObsEva SA (NASDAQ:OBSV) announced its quarterly earnings results on Thursday, November, 4th. The company reported $0.01 EPS for the quarter, beating analysts' consensus estimates of ($0.22) by $0.23.

When did ObsEva IPO?

ObsEva (OBSV) raised $98 million in an initial public offering (IPO) on Thursday, January 26th 2017. The company issued 6,500,000 shares at $14.00-$16.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO.

How do I buy shares of ObsEva?

Shares of OBSV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ObsEva own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ObsEva investors own include NIO (NIO), Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Allena Pharmaceuticals (ALNA), Bionano Genomics (BNGO) and Sorrento Therapeutics (SRNE).

Company Calendar

• Last Earnings: 11/04/2021
• Today: 9/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:OBSV
• CIK: 1685316
• Web: www.obseva.com
• Phone: (122) 552-3840
• Fax: N/A
• Employees: 50
• Year Founded: 2012

Profitability

• EPS (Trailing Twelve Months): ($0.92)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$58.38 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -416.36%
• Return on Assets: -92.01%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.61
• Quick Ratio: 0.61

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.41 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 77,971,000
• Free Float: 66,743,000
• Market Cap: $7.94 million
• Optionable: Not Optionable
• Beta: 0.68